Pages that link to "Q44427722"
Jump to navigation
Jump to search
The following pages link to Allogeneic stem cell transplantation after a fludarabine/busulfan-based reduced-intensity conditioning in patients with myelodysplastic syndrome or secondary acute myeloid leukemia. (Q44427722):
Displaying 39 items.
- Allogeneic hematopoietic cell transplantation after conditioning with 131I-anti-CD45 antibody plus fludarabine and low-dose total body irradiation for elderly patients with advanced acute myeloid leukemia or high-risk myelodysplastic syndrome (Q33560410) (← links)
- Challenges in treating older patients with acute myeloid leukemia (Q33985549) (← links)
- The role of azacitidine in the management of myelodysplastic syndromes (MDS). (Q34418429) (← links)
- Achievement of complete remission predicts outcome of allogeneic haematopoietic stem cell transplantation in patients with chronic myelomonocytic leukaemia. A study of the Chronic Malignancies Working Party of the European Group for Blood and Marrow (Q35714782) (← links)
- Transplantation in remission improves the disease-free survival of patients with advanced myelodysplastic syndromes treated with myeloablative T cell-depleted stem cell transplants from HLA-identical siblings (Q35838113) (← links)
- Allogeneic hematopoietic cell transplantation in patients age 60-70 years with de novo high-risk myelodysplastic syndrome or secondary acute myelogenous leukemia: comparison with patients lacking donors who received azacitidine (Q36029093) (← links)
- Busulfan plus fludarabine compared with busulfan plus cyclophosphamide as a conditioning regimen prior to hematopoietic stem cell transplantation in patients with hematologic neoplasms: a meta-analysis (Q36182610) (← links)
- Reduced-intensity conditioning followed by allogeneic hematopoietic cell transplantation for adult patients with myelodysplastic syndrome and myeloproliferative disorders (Q36484688) (← links)
- Stem cell transplantation with reduced-intensity conditioning regimens: a review of ten years experience with new transplant concepts and new therapeutic agents (Q36548362) (← links)
- Hematopoietic stem cell transplantation for childhood malignancies of myeloid origin (Q37051056) (← links)
- Automated detection of residual cells after sex-mismatched stem-cell transplantation - evidence for presence of disease-marker negative residual cells (Q37227738) (← links)
- Myeloablative radioimmunotherapy in conditioning prior to haematological stem cell transplantation: closing the gap between benefit and toxicity? (Q37364491) (← links)
- Red blood cell transfusion dependence and outcome after allogeneic peripheral blood stem cell transplantation in patients with de novo myelodysplastic syndrome (MDS) (Q37380958) (← links)
- The evolution of hematopoietic SCT in myelodysplastic syndrome (Q37404489) (← links)
- Allogeneic stem cell transplantation in acute myeloid leukemia: establishment of indications on the basis of individual risk stratification (Q37559330) (← links)
- Current status of allogeneic HST for chronic myelomonocytic leukemia (Q37899751) (← links)
- Hematopoietic Stem Cell Transplantation for Myelodysplastic Syndrome: A Review (Q37937818) (← links)
- Optimizing management of myelodysplastic syndromes post-allogeneic transplantation (Q37955235) (← links)
- The role of apoptosis and current therapeutic challenges in myelodysplastic syndromes. (Q40169436) (← links)
- Phase II prospective study of treosulfan-based reduced-intensity conditioning in allogeneic HSCT for hematological malignancies from 10/10 HLA-identical unrelated donor (Q43692529) (← links)
- Toxic erythema of chemotherapy following i.v. BU plus fludarabine for allogeneic PBSC transplant (Q44801887) (← links)
- Favourable outcome for patients with myeloid disorders treated with fludarabine-melphalan reduced-intensity conditioning and allogeneic bone marrow stem cell transplantation without the use of T-lymphocyte-depleting antibodies (Q44971617) (← links)
- Control of advanced and refractory acute myelogenous leukaemia with sirolimus-based non-myeloablative allogeneic stem cell transplantation (Q46608663) (← links)
- Reduced-toxicity conditioning with treosulfan, fludarabine and ATG as preparative regimen for allogeneic stem cell transplantation (alloSCT) in elderly patients with secondary acute myeloid leukemia (sAML) or myelodysplastic syndrome (MDS). (Q46896197) (← links)
- Survival benefits from reduced-intensity conditioning in allogeneic stem cell transplantation for young lower-risk MDS patients without significant comorbidities (Q53408220) (← links)
- Single center retrospective analysis of BU-based conditioning regimens in allogeneic transplantation. (Q54051617) (← links)
- Similar survival but increased toxicity with a sequential versus concurrent FluBu4 regimen (Q56835535) (← links)
- A retrospective comparison of autologous and unrelated donor hematopoietic cell transplantation in myelodysplastic syndrome and secondary acute myeloid leukemia: a report on behalf of the Chronic Leukemia Working Party of the European Group for Blood (Q57515100) (← links)
- Reduced-intensity allografting in patients with therapy-related myeloid neoplasms and active primary malignancies (Q57636771) (← links)
- The effect of allogeneic stem cell transplantation on high risk chronic lymphocytic leukaemia: a single centre retrospective analysis (Q62735936) (← links)
- Graft-versus-MDS effect after unrelated cord blood transplantation: a retrospective analysis of 752 patients registered at the Japanese Data Center for Hematopoietic Cell Transplantation (Q64055564) (← links)
- Recent publications in hematological oncology (Q75406177) (← links)
- Outcome of allo-SCT for chronic myelomonocytic leukemia (Q79819148) (← links)
- The beneficial effect of chronic graft-versus-host disease on the clinical outcome of transplantation with fludarabine/busulfan-based reduced-intensity conditioning for patients with de novo myelodysplastic syndrome (Q80464853) (← links)
- Comparison between two fludarabine-based reduced-intensity conditioning regimens before allogeneic hematopoietic stem-cell transplantation: fludarabine/melphalan is associated with higher incidence of acute graft-versus-host disease and non-relapse (Q80777921) (← links)
- Do minitransplants have minicosts? A cost comparison between myeloablative and nonmyeloablative allogeneic stem cell transplant in patients with acute myeloid leukemia (Q80933886) (← links)
- Outcome of reduced-intensity allogeneic hematopoietic stem cell transplantation (RISCT) using antilymphocyte antibodies in patients with high-risk acute myeloid leukemia (AML) (Q82488232) (← links)
- Yttrium-90-labeled anti-CD45 antibody followed by a reduced-intensity hematopoietic cell transplantation for patients with relapsed/refractory leukemia or myelodysplasia (Q90466721) (← links)
- Extra-medullary recurrence of myeloid leukemia as myeloid sarcoma after allogeneic stem cell transplantation: impact of conditioning intensity (Q96817615) (← links)